UK moves to address dire state of stroke care
This article was originally published in Clinica
Executive Summary
There can be no stronger argument for a revolutionary investment in diagnostic imaging in the UK than is shown by the need for a radical improvement in the care of stroke - or do this specialism's needs lie elsewhere? The government, clinicians and pressure groups do not know the answer to this question and the ignorance is resulting in high levels of death and morbidity, which are not even recorded correctly due to widespread delay or failures in diagnosing stroke and transient ischaemic attack (TIA).
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.